BioPharmSignal logoBioPharmSignal

Biotech News

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

ImmunityBio (IBRX)ImmunityBioFDA / regulatory

Macau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patients with BCG-unresponsive NMIBC with CIS ± papillary tumors Authorization follows a reliance-based review referencing prior FDA and EMA decisions First ANKTIVA authorization in Asia, supporting

Related news

IBRXImmunityBio2026-10-14 20:18 EST

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

IBRXImmunityBio2026-10-16 15:49 EST

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

TEVATeva Pharmaceutical Industries2026-10-09 11:00 EST

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

JNJJohnson & Johnson2026-10-23 11:09 EST

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse

ANABAnaptysBio, Inc.2026-10-19 18:18 EST

Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

BMYBMYBristol-Myers Squibb Company2026-09-30 21:32 EST

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*

REGNRegeneron Pharmaceuticals2026-10-16 11:00 EST

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

JNJJohnson & Johnson2026-10-16 10:31 EST

CHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma

URGNUroGen Pharma2026-10-19 12:00 EST

UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC

ANGOAngioDynamics2026-10-21 12:30 EST

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

View all latest news

ImmunityBio

Immune-Based Cancer Therapies ImmunityBio develops therapies that activate innate and adaptive immune responses against cancer. Its platform combines cytokine biology, cell therapy and immunotherapy combinations. ANKTIVA ANKTIVA is an IL-15 superagonist approved with BCG for selected patients with BCG-unresponsive non-muscle-invasive...

Recent company news

IBRXImmunityBio2026-11-04 13:00 EST

ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

IBRXImmunityBio2026-10-21 11:30 EST

ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer

IBRXImmunityBio2026-10-16 15:49 EST

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

IBRXImmunityBio2026-10-14 20:18 EST

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

IBRXImmunityBio2026-10-08 12:30 EST

ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium

Stock data

Close
8.01 USD
Market cap
7.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States